178672-28-1

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 41103-43-9 3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-propanol 
• 35386-24-4 1-(2-Methoxyphenyl)piperazine 

Downstream Products

• 1085927-87-2 7-((3-(4-(2-Methoxyphenyl)piperazin-1-yl)propoxy)methyl)-3,4-dihydroquinolin-2(1H)-one 
• 1186236-58-7 1‐(3‐azidopropyl)‐4‐(2‐methoxyphenyl)piperazine 
• 1161392-63-7 C₃₀H₄₁F₉N₆O₄ 

Relevant academic research and scientific papers

2-Amino-3-(1-(4-(4-(2-methoxyphenyl) piperazine-1-yl)butyl)-1H-1,2,3- triazol-4-yl) propanoic acid: Synthesized, 99mTc-tricarbonyl labeled, and bioevaluated as a potential 5HT1A receptor ligand

To develop a novel 5HT1A receptor imaging agent, a new methoxyphenyl piperazine derivative was synthesized and radiolabeled with 99mTc-tricarbonyl precursor. We used the Cu (I)-catalyzed cycloaddition of azide and terminal alkynes to

COMPSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINE BASED ATYPICAL ANTIPSYCHOTIC AGENTS

The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.

N-[3-[4-(2-methoxyphenyl) piperaziny-1-yl]propyl]cyclam: Synthesized as a potential 5-HT1A receptor ligand and labelled with 99mTc-nitrido core

This paper reports the synthesis of new potential 5-HT1A receptor ligand N-[3-[4-(2-methoxyphenyl)piperaziny-1-yl]propyl]cyclam (MPPC) and radiolabelling of it with 99mTc-nitrido core. The novel neutral complex 99mTcN-MPPC

Utility of azetidinium methanesulfonates for radiosynthesis of 3-[ 18F]fluoropropyl amines

3-Methanesulfonyloxypropyl tertiary amines were observed to cyclize to form azetidinium methanesulfonate moieties. Heat-induced cyclization of 3-methanesulfonyloxypropyl amines was utilized for preparation of azetidinium methanesulfonates. The azetidinium methanesulfonates were found to incorporate radioactive [18F]fluoride (decay-corrected yields > 60%) efficiently, resulting in an efficient synthesis of 3-[18F] fluoropropyl tertiary amines. Copyright

N-Arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective α1-adrenoceptor antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype- selective antagonists by functional in vitro screening. 3-[4-(ortho- Substituted phenyl)piperazin-1:yl]propylamines were derivatized with N,N- dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4- b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a 'negative screen' for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the α(1D)-AR.

[3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy]-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists

The present invention relates to novel α 1 -adrenoceptor antagonists of Formula I: STR1 in which: p is 0 or 1;t is 0, 1 or 2;X is O, S or NR 6 (in which R 6 is hydro or (C 1-6)alkyl);Y and Z are independently CH or N;R 1 is hydro, hydroxy, halo, nitro, amino, cyano, (C 1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C 1-6)alkyl, (C 3-6)cycloalkyl, (C 3-6)cycloalkyl (C 1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C 1-4)alkyl, heteroaryl (C 1-4)alkyl, (C 1-6)alkyloxy, (C 3-6)cycloalkyloxy, (C 3-6)cycloalkyl (C 1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C 1-4)alkyloxy or heteroaryl (C 1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano);R 2 is hydro, hydroxy, halo, cyano, (C 1-6)alkyl or (C 1-6)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms);R 3 is -C (O)R 7 (wherein R 7 is (C 1-6)alkyl, (C 3-6)cycloalkyl, di(C 1-4)alkylamino, N-(C 1-4)alkyl-N-(C 1-4)alkyloxyamino, (C 1-4)alkyl((C 1-4)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl);R 4 is halo, hydroxy, cyano, (C 1-6)alkyl or (C 1-6)alkyloxy; andR 5 is (C 1-6)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.